NEW_CURA-LEAF_1170x120_OCT

Joseph Papa

Gordon named U.S. president of Bausch + Lomb

Gordon named U.S. president of Bausch + Lomb

BRIDGEWATER, N.J. – Bausch + Lomb announced that Joseph Gordon has been named U.S. president, Bausch + Lomb. In this role, Gordon will oversee the fully integrated U.S. eye care business, inclusive of all four business units – Vision Care, Consumer Health, Surgical and Pharmaceuticals – reporting directly to chairman and chief executive officer of

Bausch+Lomb releases Vyzulta

Bausch+Lomb releases Vyzulta

LAVAL, Quebec — Bausch+Lomb has begun rolling out Vyzulta (latanoprostene bunod ophthalmic solution 0.024%) to U.S. pharmaceutical distributors. The Valeant Pharmaceuticals International subsidiary said Vyzulta is slated to become available to patients at pharmacies across the United States in the next few days. The first prostaglandin analog with one of its metabolites being nitric oxide,

Valeant to sell iNova Pharmaceuticals for $930 million

Valeant to sell iNova Pharmaceuticals for $930 million

LAVAL, Quebec — Valeant Pharmaceuticals International Inc. plans to sell its iNova Pharmaceuticals unit for $930 million in cash to help pay down debt. Valeant said Thursday that iNova, whose portfolio includes prescription drugs and over-the-counter health products, is being sold to a company jointly owned by funds of Pacific Equity Partners and Carlyle Group LP.

L’Oréal buys CeraVe, AcneFree, Ambi brands from Valeant

L’Oréal buys CeraVe, AcneFree, Ambi brands from Valeant

CLICHY, N.Y., and LAVAL, Quebec — L’Oréal plans to acquire the CeraVe, AcneFree and Ambi skin care brands from Valeant Pharmaceuticals International Inc. for $1.3 billion in cash. Plans call for CeraVe, AcneFree and Ambi to become part of the L’Oréal Active Cosmetics Division, which includes the La Roche-Posay, Vichy and SkinCeuticals brands developed with

Zoetis executive joins Valeant as CFO

Zoetis executive joins Valeant as CFO

NEW YORK — Paul Herendeen has left Zoetis Inc. to become executive vice president of finance and chief financial officer at Valeant Pharmaceuticals International Inc. Valeant said Monday that Herendeen takes over the CFO role from Robert Rosiello, who has been appointed executive vice president of corporate development and strategy. “I am pleased to bring

Valeant makes changes to executive team

Valeant makes changes to executive team

LAVAL, Quebec — Valeant Pharmaceuticals International Inc. has instituted a series of leadership and organizational changes, including an expansion of its executive committee and the duties of some senior executives. Valeant said Christina Ackermann has joined the company as executive vice president and general counsel of Valeant, succeeding Robert Chai-Onn, who will be leaving Valeant

WBA’s Gourlay: We’ll work with Valeant

WBA’s Gourlay: We’ll work with Valeant

During the Walgreens Boots Alliance’s conference call this week on its third-quarter results, co-COO Alex Gourlay told analysts that WBA will address Valeant Pharmaceuticals International’s concerns about its distribution arrangement with the company. Under the deal, announced in December, WBA and Valeant entered agreements in which the drug maker will directly distribute branded prescription drugs

Bausch + Lomb expands PreserVision AREDS line

Bausch + Lomb expands PreserVision AREDS line

LAVAL, Quebec — Bausch + Lomb has rolled out PreserVision AREDS 2 Formula + Multivitamin, a two-in-one eye supplement aimed at making it simpler for consumers to get their nutrients. The Valeant Pharmaceuticals International subsidiary said Thursday that PreserVision AREDS 2 Formula + Multivitamin is the first leading brand to combine the National Eye Institute-recommended

Valeant names Perrigo’s Papa as chairman, CEO

Valeant names Perrigo’s Papa as chairman, CEO

NEW YORK — Joseph Papa has resigned as chairman and chief executive officer of Perrigo Co. plc to join Valeant Pharmaceuticals International Inc. as chairman and CEO. Valeant said Monday that Papa, 60, is slated to start at the company by early May. Papa will succeed J. Michael Pearson, who is expected to remain as

Perrigo rolls out store-brand Glucerna shake

Perrigo rolls out store-brand Glucerna shake

DUBLIN, Ireland — Perrigo Co. plc has begun shipping a store-brand version of Abbott’s Glucerna aseptic nutritional shake for adults with diabetes. Perrigo said Tuesday that its product represents a first-to-market launch of an over-the-counter, private-brand equivalent to Glucerna. The company said its product is packaged and marketed as a store brand or retailer “own

Perrigo, Allergan release Mucinex store-brand tablets

Perrigo, Allergan release Mucinex store-brand tablets

DUBLIN, Ireland — Perrigo Co. plc and Allergan plc have begun shipping 1,200-mg guaifenesin extended-release tablets, an expectorant, to retail and wholesale customers. The companies said this week that the over-the-counter product, a generic equivalent to Reckitt Benckiser’s Mucinex ER tablets (guaifenesin 1,200 mg), is packaged and marketed as store brands or retailer own-label brands. “This

Perrigo recalls store-brand children’s guaifenesin liquid

Perrigo recalls store-brand children’s guaifenesin liquid

DUBLIN, Ireland — Perrigo Co. plc has voluntarily recalled some batches of its children’s guaifenesin liquid in the United States following a recent recall of certain dosing cups by its supplier. Perrigo said Monday that the recall, to the retail level, involves two batches of its children’s guaifenesin grape liquid (100 mg/5 ml), an expectorant,

Allergan, Perrigo launch store-brand Mucinex D

Allergan, Perrigo launch store-brand Mucinex D

DUBLIN, Ireland — Allergan plc and Perrigo Co. plc have launched combination guaifenesin 600-mg and pseudoephedrine HCl 60-mg extended-release tablets to retail and wholesale customers. Allergan and Perrigo said Monday that the initial shipments of the new store-brand product, which began in December, mark a first-to-market achievement for the companies. “This first-to-market launch illustrates the